Ticker Symbol: PDSB
PDS Biotechnology Corporation
$10.72 - 02-12-2024 4 p.m. ET
Exchange: NASDAQ
Country:
United States
Currency:
USD
Asset
Type: Common Stock
CIK:0001472091
Company Profile
PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology platform. Versamune® effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them.
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: 25B Vreeland Road
Website: www.pdsbiotech.com
CEO: Frank Bedu-Addo
Tags:
- Biotechnology
- Pharmaceuticals: Major
- Health Technology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Pricing
Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $4.01
Change:
-$0.68
(
-14.47%)
Days Range: $3.91 - $4.84
Beta: 1.98
52wk. High: $13.65
52wk. Low: $3.88
Ytd. Change -78.86%
50 Day Moving Average: $5.08
200 Day Moving Average: $5.86
Shares Outstanding: 30868188
Valuation
Market Cap: 12.4B
PE Ratio: -
EPS (TTM): 0
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A